Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Dec 24;81(5):943-949.
doi: 10.1093/cid/ciaf192.

A Case-Control Study of Hepatitis C Virus Reinfection in Incarcerated Patients in California Receiving Medication for Opioid Use Disorder

Joey Shemuel  1 , Amy T Krawiec  2 , Donna Kalauokalani  2 , Kimberley D Lucas  2
Affiliations

A Case-Control Study of Hepatitis C Virus Reinfection in Incarcerated Patients in California Receiving Medication for Opioid Use Disorder

Joey Shemuel et al. Clin Infect Dis. .

Abstract

Background: Incarcerated people are disproportionately burdened with hepatitis C virus (HCV) infection and experience elevated risk of reinfection following treatment. Medication for opioid use disorder (MOUD) has been shown to reduce, but not eliminate, reinfection. Research is lacking on patient-level factors associated with HCV reinfection in incarcerated populations in the United States receiving MOUD.

Methods: We conducted a case-control study from secondary data analysis of health records among people incarcerated in California state prisons who initiated HCV treatment, achieved sustained virologic response, and began MOUD before sustained virologic response. Case-patients were reinfected within 1 year; controls remained HCV-negative at 1 year.

Results: Eligible subjects (50 cases; 108 controls) were predominantly male (96.2%), Hispanic/Latinx (62.7%) or White (29.1%), and median age 36 (range, 23-60) years. HCV reinfection was independently associated with injection drug use (adjusted odds ratio [aOR] = 3.4; 95% confidence interval [CI], 1.3-8.5), unsterile tattooing (aOR = 3.4; 95% CI, 1.2-9.9), methamphetamine use (aOR = 2.5; 95% CI, 1.0-6.1), younger age (aOR = 0.7; 95% CI, .5-.9; units = 5 years), and lower adherence to adequately dosed (≥16 mg/day) buprenorphine (aOR = 0.7; 95% CI, .6-1.0; units = 0.25, aOR = 0.3; 95% CI, .1-.9; units = 1.0).

Conclusions: Even with complete MOUD adherence, conferring a 70% protective effect for HCV reinfection, patients reported ongoing risk behaviors. Injection drug use, methamphetamine use, and unsterile tattooing also increase the risk of other bloodborne or skin and soft tissue infections and overdose. Improved health outcomes could be achieved with integrating enhanced monitoring of MOUD with expanded harm reduction including syringe services and contingency management for treatment of stimulant use disorders.

Keywords: harm reduction; hepatitis C; opioid use disorder; people who inject drugs; prison.

PubMed Disclaimer

Conflict of interest statement

Potential conflicts of interest. The authors: No reported conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest.

MeSH terms

Substances